Literature DB >> 29663862

Dynamics and structural stability effects of germline PTEN mutations associated with cancer versus autism phenotypes.

Iris Nira Smith1, Stetson Thacker1,2, Ritika Jaini1,3,2, Charis Eng1,4,5,3,2.   

Abstract

Individuals with germline mutations in the tumor suppressor gene phosphatase and tensin homolog (PTEN), irrespective of clinical presentation, are diagnosed with PTEN hamartoma tumor syndrome (PHTS). PHTS confers a high risk of breast, thyroid, and other cancers or autism spectrum disorder (ASD) with macrocephaly. It remains unclear why mutations in one gene can lead to seemingly disparate phenotypes. Thus, we sought to identify differences in ASD vs. cancer-associated germline PTEN missense mutations by investigating putative structural effects induced by each mutation. We utilized a theoretical computational approach combining in silico structural analysis and molecular dynamics (MD) to interrogate 17 selected mutations from our patient population: six mutations were observed in patients with ASD (only), six mutations in patients with PHTS-associated cancer (only), four mutations shared across both phenotypes, and one mutation with both ASD and cancer. We demonstrate structural stability changes where all six cancer-associated mutations showed a global decrease in structural stability and increased dynamics across the domain interface with a proclivity to unfold, mediating a closed (inactive) active site. In contrast, five of the six ASD-associated mutations showed localized destabilization that contribute to the partial opening of the active site. Our results lend insight into distinctive structural effects of germline PTEN mutations associated with PTEN-ASD vs. those associated with PTEN-cancer, potentially aiding in identification of the shared and separate molecular features that contribute to autism or cancer, thus, providing a deeper understanding of genotype-phenotype relationships for germline PTEN mutations.

Entities:  

Keywords:  ASD: Autism spectrum disorder; ATP: Adenosine triphosphate; ENCoM: Elastic network contact model; GROMACS: Groningen machine for chemical simulations; LINCS: Linear constraint solver; MD: Molecular dynamics; NMA: Normal mode analysis; PCA: Principal component analysis; PDB: Protein data bank; PHTS: hamartoma tumor syndrome; PIP: Phosphatidylinositol-3,4,5-triphosphate; PIP: Phosphatidylinositol-4,5-biphosphate; PME: Particle mesh Ewald; PTEN; PTEN: Phosphatase and tensin homolog deleted on chromosome ten; RMSD: Root mean square deviation; Rg: Radius of gyration; VMD: Visual Molecular Dynamics; WT: Wild-type; autism; cancer; molecular dynamics simulations; poly(Glu-pTyr): Polymers of glutamate and tyrosine, 1:1 ratio; protein structure stability

Mesh:

Substances:

Year:  2018        PMID: 29663862      PMCID: PMC6235728          DOI: 10.1080/07391102.2018.1465854

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  59 in total

1.  Will the real Cowden syndrome please stand up: revised diagnostic criteria.

Authors:  C Eng
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

2.  Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.

Authors:  M M Georgescu; K H Kirsch; P Kaloudis; H Yang; N P Pavletich; H Hanafusa
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 3.  PTEN gene and integrin signaling in cancer.

Authors:  M Tamura; J Gu; H Tran; K M Yamada
Journal:  J Natl Cancer Inst       Date:  1999-11-03       Impact factor: 13.506

Review 4.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase.

Authors:  T Maehama; J E Dixon
Journal:  Trends Cell Biol       Date:  1999-04       Impact factor: 20.808

Review 5.  PTEN and myotubularin: novel phosphoinositide phosphatases.

Authors:  T Maehama; G S Taylor; J E Dixon
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

6.  Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Authors:  J O Lee; H Yang; M M Georgescu; A Di Cristofano; T Maehama; Y Shi; J E Dixon; P Pandolfi; N P Pavletich
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

7.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.

Authors:  D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

8.  Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.

Authors:  S Y Han; H Kato; S Kato; T Suzuki; H Shibata; S Ishii; K Shiiba; S Matsuno; R Kanamaru; C Ishioka
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

Review 9.  Protean PTEN: form and function.

Authors:  Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

10.  Retinal angioma in a patient with Cowden disease.

Authors:  Jean-Jacques Gicquel; Pierre Vabres; Dominique Bonneau; Martial Mercié; Latifa Handiri; Paul Dighiero
Journal:  Am J Ophthalmol       Date:  2003-03       Impact factor: 5.258

View more
  16 in total

1.  Autism-associated SHANK3 missense point mutations impact conformational fluctuations and protein turnover at synapses.

Authors:  Michael Bucher; Stephan Niebling; Yuhao Han; Dmitry Molodenskiy; Fatemeh Hassani Nia; Hans-Jürgen Kreienkamp; Dmitri Svergun; Eunjoon Kim; Alla S Kostyukova; Michael R Kreutz; Marina Mikhaylova
Journal:  Elife       Date:  2021-05-04       Impact factor: 8.140

2.  An Integrated Deep-Mutational-Scanning Approach Provides Clinical Insights on PTEN Genotype-Phenotype Relationships.

Authors:  Taylor L Mighell; Stetson Thacker; Eric Fombonne; Charis Eng; Brian J O'Roak
Journal:  Am J Hum Genet       Date:  2020-05-21       Impact factor: 11.025

Review 3.  PTEN-opathies: from biological insights to evidence-based precision medicine.

Authors:  Lamis Yehia; Joanne Ngeow; Charis Eng
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

4.  Conformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer.

Authors:  Iris Nira Smith; Stetson Thacker; Marilyn Seyfi; Feixiong Cheng; Charis Eng
Journal:  Am J Hum Genet       Date:  2019-04-18       Impact factor: 11.025

5.  Structural and Dynamic Effects of PTEN C-Terminal Tail Phosphorylation.

Authors:  Iris N Smith; Jennifer E Dawson; James Krieger; Stetson Thacker; Ivet Bahar; Charis Eng
Journal:  J Chem Inf Model       Date:  2022-08-24       Impact factor: 6.162

Review 6.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Yonglan Liu; Chung-Jung Tsai; Hyunbum Jang
Journal:  J Mol Biol       Date:  2022-04-01       Impact factor: 6.151

Review 7.  PTEN in Hereditary and Sporadic Cancer.

Authors:  Joanne Ngeow; Charis Eng
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

Review 8.  Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.

Authors:  Ruth Nussinov; Mingzhen Zhang; Chung-Jung Tsai; Hyunbum Jang
Journal:  Mol Cancer Res       Date:  2020-12-07       Impact factor: 6.333

Review 9.  Structural Mechanisms of PTEN Regulation.

Authors:  Glenn R Masson; Roger L Williams
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

10.  The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane.

Authors:  Hyunbum Jang; Iris Nira Smith; Charis Eng; Ruth Nussinov
Journal:  iScience       Date:  2021-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.